<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3451">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581577</url>
  </required_header>
  <id_info>
    <org_study_id>286495</org_study_id>
    <nct_id>NCT04581577</nct_id>
  </id_info>
  <brief_title>Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders</brief_title>
  <acronym>CLASSIC</acronym>
  <official_title>Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate perceived clinical and psychosocial experiences of patients and&#xD;
      their families during the Covid-19 pandemic. it is important to understand the implications&#xD;
      of the pandemic for this population, particularly given its likely protracted course, and&#xD;
      resultant limitations to daily activities and clinical care. This will help clinicians plan&#xD;
      support and adaptations to the services they provide in the medium to long term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">December 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative evaluation of the perceived clinical and psychosocial impact of the Covid-19 pandemic in patients with neuromuscular and neurological disorders</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of semi-structured questionnaires using thematic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of the proportion of patients with NMD who have had suspected or confirmed Covid-19 infection during the pandemic</measure>
    <time_frame>4 months</time_frame>
    <description>Quantitative analysis of the proportion of questionnaire respondents reporting confirmed or suspected Covid-19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative evaluation of the social environment of patients with NMDs</measure>
    <time_frame>4 months</time_frame>
    <description>Qualitative analysis describing the social environment of patients with NMDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative evaluation of the social activities of patients with NMDs</measure>
    <time_frame>4 months</time_frame>
    <description>Qualitative analysis describing the social activities of patients with NMDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative evaluation of the professional activities of patients with NMDs</measure>
    <time_frame>4 months</time_frame>
    <description>Qualitative analysis describing the professional activities of patients with NMDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative evaluation of the impact of the Covid-19 pandemic on families of patients with neuromuscular and neurological disorders</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of semi-structured questionnaires using thematic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative evaluation of concerns regarding medical care from the perspective of patients with NMDs and their families during the Covid-19 pandemic</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of semi-structured questionnaires using thematic analysis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Neuromuscular Diseases</condition>
  <condition>Neurological Diseases or Conditions</condition>
  <arm_group>
    <arm_group_label>Adult patients with neuromuscular or neurological disorders</arm_group_label>
    <description>Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents of paediatric patients with neuromuscular or neurological disorders</arm_group_label>
    <description>Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Semi-structured telephone questionnaire</intervention_name>
    <description>Semi-structured telephone questionnaire</description>
    <arm_group_label>Adult patients with neuromuscular or neurological disorders</arm_group_label>
    <arm_group_label>Parents of paediatric patients with neuromuscular or neurological disorders</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of a neuromuscular and/or neurological disorder including&#xD;
        Duchenne muscular dystrophy, spinal muscular atrophy, congenital muscular dystrophies, and&#xD;
        other neuromuscular and neurological disorders&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult group&#xD;
&#xD;
          -  Patient over 16 years of age with a confirmed diagnosis of neuromuscular and/or&#xD;
             neurological disorder&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Paediatric group&#xD;
&#xD;
          -  Parent of a patient under 16 years of age with a confirmed diagnosis of neuromuscular&#xD;
             and/or neurological disorder&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling for telephone questionnaire to be audio-recorded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Simonds, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lydia Spurr, MBBS</last_name>
    <phone>0207 352 8121</phone>
    <email>l.spurr@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia A Spurr, MBBS BMedSci</last_name>
      <phone>0207 352 8121</phone>
      <email>l.spurr@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anita K Simonds, MD MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin R Cowie, MD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Morrell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kinesh Patel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

